Biocon signs licensing and supply pact with Biomm S.A for Semaglutide commercialisation in Brazil
Express Pharma
APRIL 18, 2024
Semaglutide (gOzempic), which is used to improve glycemic control in adults with type-2 diabetes Biocon announced the signing of an exclusive licensing and supply agreement with Biomm S.A., Biomm focuses on developing, manufacturing and commercialising complex biotech and biosimilar drug products at their production facility in Nova Lima.
Let's personalize your content